Among HBeAg+ patients with HBV DNA level ≥8 log10 IU/mL and Anti-HBc level<3 log10 IU/mL at baseline, 81.8% had PV at week 78 compared with 10.1% of HBeAg- patients with HBV DNA level<8 log10 IU/mL and Anti-HBc level ≥3 log10 IU/mL (P<0.001) (Figure 3). Here, KRT88P is linked to acquired polycythemia vera.